News

When the Cancer Patient Isn't a Kid Anymore


 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

"The lengthy insurance retention of adolescent/young adult cancer survivors makes a vertically integrated medical care system an ideal population laboratory for adolescent/young adult cancer survivorship research," they wrote in a poster presented at ASCO 2012.

Patient, Advocate for Thyself

Dr. Sadak said that patients also have to be willing to step up to the plate and act as their own best advocates.

"At some point, we as the provider want to educate the patient ... to have some kind of responsibility for their own health care," he said. "The question is, at what age? It may not be 16, 17, or 18, especially in a population that’s been through a serious illness like childhood cancer. The bonds that these patients and their parents have created are very strong. We have to respect that, while still encouraging the survivor to take responsibility for his health."

Dr. Sadak’s study was funded by a Children’s Health Center Board grant. Dr. Suh’s study was funded by the National Institutes of Health. Dr. Cooper’s study was supported by Kaiser Permanente. All authors reported having no relevant conflicts of interest.

Pages

Recommended Reading

Teens and Young Adults Trail Children on Pediatric Leukemia Regimens
MDedge Hematology and Oncology
Hodgkin's Survivors Face High Breast Cancer Risk
MDedge Hematology and Oncology
As CT Scans Increase, Concern of Radiation Risk Rises
MDedge Hematology and Oncology
Diagnostic Imaging on the Rise Even in 'Accountable' HMOs
MDedge Hematology and Oncology
FDA Announces Limited Leucovorin Recall
MDedge Hematology and Oncology
FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Hematology and Oncology
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Hematology and Oncology
Traffic-Related Toxins Linked to Childhood Kidney Cancer
MDedge Hematology and Oncology
Flu Vaccine Approved for Upcoming Season
MDedge Hematology and Oncology
Drug for aHUS effective but expensive
MDedge Hematology and Oncology